Evidence map›Paper›PMID 33119072›Full record

ArticleThe Journal of infectious diseases2021

Parasite Viability as a Superior Measure of Antimalarial Drug Activity in Humans.

Maria Rebelo, Rebecca Pawliw, Jeremy Gower, Lachlan Webb, Hayley Mitchell, Zuleima Pava, Rebecca E Watts, Miles P Davenport, James S McCarthy, David S Khoury

Abstract read
PubMed Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. IncompleteFrontiers in cellular and infection microbiology · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. NewAntimicrobial agents and chemotherapy · 2022
    Article
  8. Parasite Viability as a Measure ofAntimicrobial agents and chemotherapy · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Maria RebeloQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Rebecca PawliwQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Jeremy GowerQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Lachlan WebbQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Hayley MitchellQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Zuleima PavaQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Rebecca E WattsQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
Miles P DavenportKirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia.
James S McCarthyQIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.
David S KhouryKirby Institute, University of New South Wales (Sydney), Sydney, New South Wales, Australia.ORCID 0000-0002-2663-1551
QIMR Berghofer Medical Research Institute · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundArtemisinin derivatives are the leading class of antimalarial drugs due to their rapid onset of action and rapid clearance of circulating parasites. The parasite clearance half-life measures the rate of loss of parasites from blood after treatment, and this is currently used to assess antimalarial activity of novel agents and to monitor resistance. However, a number of recent studies have challenged the use of parasite clearance to measure drug activity, arguing that many circulating parasites may be nonviable.

methodsPlasmodium falciparum-infected subjects (n = 10) in a malaria volunteer infection study were administered a single dose of artesunate (2 mg/kg). Circulating parasite concentration was assessed by means of quantitative polymerase chain reaction (qPCR). Parasite viability after artesunate administration was estimated by mathematical modeling of the ex vivo growth of parasites collected from subjects.

resultsWe showed that in artemisinin-sensitive infection, viable parasites declined to <0.1% of baseline within 8 hours after artesunate administration, while the total number of circulating parasites measured with quantitative polymerase chain reaction remained unchanged. In artemisinin-resistant infections over the same interval, viable parasites declined to 51.4% (standard error of the mean, 4.6%) of baseline.

conclusionsThese results demonstrate that in vivo drug activity of artesunate is faster than is indicated by the parasite clearance half-life.

Indexed as

AntimalarialsArtemisininsArtesunateMalaria, FalciparumPlasmodium falciparumDrug ResistanceHumansModels, TheoreticalAntimalarialsArtemisininsArtesunateantimalarialdrug developmentefficacyMalariaparasite clearanceviability

Identifiers

PMID33119072
OpenAlexW3095233190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.